Sukul, Devraj <br/><br/>
The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).  [electronic resource] 

 -  Journal of interventional cardiology  Aug 2017 
 - 291-300 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1540-8183 
<br/><br/><label>Standard No.: </label>10.1111/joic.12388  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Aged<br/>Antibodies, Monoclonal--therapeutic use<br/>Blue Cross Blue Shield Insurance Plans<br/>Contraindications, Drug<br/>Eptifibatide<br/>Female<br/>Heparin--therapeutic use<br/>Humans<br/>Immunoglobulin Fab Fragments--therapeutic use<br/>Male<br/>Michigan<br/>Middle Aged<br/>Myocardial Infarction--therapy<br/>Peptides--therapeutic use<br/>Percutaneous Coronary Intervention<br/>Platelet Aggregation Inhibitors--therapeutic use<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Postoperative Complications--epidemiology<br/>Renal Dialysis<br/>Retrospective Studies<br/>Treatment Outcome